- Home
- CDMO vs ERAS Comparison
CDMO vs ERAS Comparison
Compare CDMO & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDMO
- ERAS
- Stock Information
- Founded
- CDMO 1981
- ERAS 2018
- Country
- CDMO United States
- ERAS United States
- Employees
- CDMO N/A
- ERAS N/A
- Industry
- CDMO Biotechnology: Pharmaceutical Preparations
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- CDMO Health Care
- ERAS Health Care
- Exchange
- CDMO Nasdaq
- ERAS Nasdaq
- Market Cap
- CDMO 784.1M
- ERAS 723.8M
- IPO Year
- CDMO N/A
- ERAS 2021
- Fundamental
- Price
- CDMO $12.36
- ERAS $2.59
- Analyst Decision
- CDMO Buy
- ERAS Strong Buy
- Analyst Count
- CDMO 5
- ERAS 5
- Target Price
- CDMO $13.63
- ERAS $5.90
- AVG Volume (30 Days)
- CDMO 1.3M
- ERAS 1.2M
- Earning Date
- CDMO 12-10-2024
- ERAS 11-12-2024
- Dividend Yield
- CDMO N/A
- ERAS N/A
- EPS Growth
- CDMO N/A
- ERAS N/A
- EPS
- CDMO N/A
- ERAS N/A
- Revenue
- CDMO $150,445,000.00
- ERAS N/A
- Revenue This Year
- CDMO $19.05
- ERAS N/A
- Revenue Next Year
- CDMO $20.88
- ERAS N/A
- P/E Ratio
- CDMO N/A
- ERAS N/A
- Revenue Growth
- CDMO 6.75
- ERAS N/A
- 52 Week Low
- CDMO $5.65
- ERAS $1.64
- 52 Week High
- CDMO $12.48
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- CDMO 67.27
- ERAS 42.73
- Support Level
- CDMO $12.11
- ERAS $2.51
- Resistance Level
- CDMO $12.39
- ERAS $2.68
- Average True Range (ATR)
- CDMO 0.09
- ERAS 0.21
- MACD
- CDMO -0.05
- ERAS -0.04
- Stochastic Oscillator
- CDMO 89.29
- ERAS 14.56
About CDMO Avid Bioservices Inc.
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.